Cyanotech Corp (OTCPK:CYAN)
$ 0.49 +0.030 (+6.52%) Market Cap: 3.55 Mil Enterprise Value: 14.88 Mil PE Ratio: 0 PB Ratio: 0.46 GF Score: 23/100

Q1 2025 Cyanotech Corp Earnings Call Transcript

Aug 09, 2024 / 12:00AM GMT
Release Date Price: $0.6799 (-4.90%)

Key Points

Positve
  • Net sales increased by 15% compared to the prior year, driven by higher sales of astaxanthin.
  • Launch of Hawaiian Spirulina gummies in May to complement existing product offerings.
  • Operating loss decreased by $200,000 compared to the first quarter of fiscal 2024.
  • Preliminary financing secured to meet market demand and support future growth.
  • Positive outlook on consumer interest in sustainable, high-quality dietary supplements.
Negative
  • Gross profit margin decreased by 4.8 percentage points due to higher costs from lower production volumes.
  • Gross profit remained flat at $1.5 million despite increased sales.
  • Net loss for the quarter was $1.2 million, slightly improved but still significant.
  • Working capital decreased significantly from $2 million to $207,000.
  • Reclassification of $1 million of debt from long term to short term, impacting financial flexibility.
Matthew Custer
Cyanotech Corp - President, Chief Executive Officer, Director

Hello all from Kona, Hawaii. Thank you all for joining us today to report Cyanotech's first quarter fiscal year 2025 earnings results. I am Matt Custer, President and Chief Executive Officer of Cyanotech. Joining me on the call today is Felicia Ladin, our Chief Financial Officer. I will turn the call over to Felicia to provide our forward-looking statement.

Felicia Ladin
Cyanotech Corp - Chief Financial Officer, Vice President of Finance and Administration, Treasurer

Thanks, Matt. Our discussion today may include forward-looking statements. We do not undertake any obligation to update forward-looking statements either as a result of new information, future events, or otherwise. Our actual results may differ materially from what is described in these forward-looking statements.

Some of the factors that may cause results to differ are listed in our publicly filed documents. For additional information, we encourage you to review our 10-Q and fiscal year 2024 10-K report filed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot